Y Intercept Hong Kong Ltd decreased its holdings in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Free Report) by 69.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,379 shares of the company’s stock after selling 33,204 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $306,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of FMS. Pzena Investment Management LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 85.4% in the 4th quarter. Pzena Investment Management LLC now owns 24,332,192 shares of the company’s stock valued at $397,588,000 after buying an additional 11,209,015 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 77.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,570,817 shares of the company’s stock valued at $25,667,000 after purchasing an additional 683,851 shares during the period. Millennium Management LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at $16,738,000. BlackRock Inc. boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 240.0% in the 3rd quarter. BlackRock Inc. now owns 404,730 shares of the company’s stock valued at $5,682,000 after purchasing an additional 285,705 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth about $3,436,000. 6.66% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on FMS shares. Citigroup started coverage on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 1st. They set a “neutral” rating for the company. UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Monday. Truist Financial raised their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $26.00 to $28.00 and gave the company a “hold” rating in a research report on Thursday, July 13th. StockNews.com started coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Thursday. They issued a “strong-buy” rating for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to a “hold” rating in a research report on Friday, April 28th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $29.89.
Fresenius Medical Care AG & Co. KGaA Stock Down 0.7 %
Fresenius Medical Care AG & Co. KGaA stock opened at $24.36 on Friday. The company’s 50 day simple moving average is $24.91 and its 200 day simple moving average is $22.55. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $12.78 and a fifty-two week high of $27.72. The firm has a market capitalization of $14.30 billion, a price-to-earnings ratio of 23.20 and a beta of 1.06. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.26 and a quick ratio of 0.91.
Fresenius Medical Care AG & Co. KGaA Profile
Fresenius Medical Care AG & Co KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Articles
- Five stocks we like better than Fresenius Medical Care AG & Co. KGaA
- Space Investment: How to Invest in Space Exploration
- 7 Best Bear Market ETFs to Battle a Market Decline
- How to Invest in Social Media
- How to Invest in Wheat: Is it a Hedge Against Inflation?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Walmart Wins the Retail Wars: Target is Losing Ground
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
